Contrast-induced nephropathy in interventional cardiology

International Journal of Nephrology and Renovascular Disease

Volumn 4, Issue , 2011, Pages 85-99

  Sudarsky, Doron ^a   Nikolsky, Eugenia ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Acute kidney injury; Contrast media; Contrast induced nephropathy; Percutaneous coronary intervention

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CONTRAST MEDIUM; CREATININE; CYSTATIN C; DIATRIZOATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; ENDOTHELIN; FENOLDOPAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IOBITRIDOL; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; IOVERSOL; MEGLUMINE DIATRIZOATE; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; PROSTAGLANDIN E1; SERUM ALBUMIN; SIMVASTATIN; THEOPHYLLINE; UNCLASSIFIED DRUG; XENETRIX;

ACUTE KIDNEY FAILURE; AGE; ALBUMIN BLOOD LEVEL; ANEMIA; ANGIOCARDIOGRAPHY; CHRONIC KIDNEY FAILURE; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEHYDRATION; DIABETES MELLITUS; DIURESIS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYDRATION; HYPOTENSION; INCIDENCE; INFUSION SYSTEM; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; KIDNEY GRAFT; LOW DRUG DOSE; NONHUMAN; OSMOLARITY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; RENAL REPLACEMENT THERAPY; REVIEW; SCORING SYSTEM; SIDE EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; VISCOSITY;

EID: 84155178188     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. DeFrances CJ, Hall MJ. 2005 National Hospital Discharge Survey. Adv Data. 2007;(385):1-19.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart Disease and Stroke Statistics - 2011 Update: a Report From the American Heart Association. Circulation. 2011;123(4):e18-e209.
3. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103(5):368-375.
4. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259-2264.
5. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115(25):3189-3196.
6. Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the US Food and Drug Administration. Radiolog y. 1997;203(3):605-610.
7. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995;47(1):254-261.
8. Rich M W, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insuffciency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med. 1990; 150(6):1237-1242.
9. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354(4):379-386.
10. Parfrey PS, Griffths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insuffciency, or both. A prospective controlled study. N Engl J Med. 1989;320(3): 143-149.
11. Blank DW, Nanji AA. Ketone interference in estimation of urinary creatinine; effect on creatinine clearance in diabetic ketoacidosis. Clin Biochem. 1982;15(6):279-280.
12. Gerard SK, Khayam-Bashi H. Characterization of creatinine error in ketotic patients. A prospective comparison of alkaline picrate methods with an enzymatic method. Am J Clin Pathol. 1985;84(5):659-664.
13. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR. Serum creatinine levels correlate with plasma amyloid beta protein. Alzheimer Dis Assoc Disord. 2002;16(3):187-190.
14. Hyneck ML, Berardi RR, Johnson RM. Interference of cephalosporins and cefoxitin with serum creatinine determination. Am J Hosp Pharm. 1981;38(9):1348-1352.
15. Srisawasdi P, Chaichanajarernkul U, Teerakanjana N, Vanavanan S, Kroll MH. Exogenous interferences with Jaffe creatinine assays: addition of sodium dodecyl sulfate to reagent eliminates bilirubin and total protein interference with Jaffe methods. J Clin Lab Anal. 2010; 24(3):123-133.
16. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest. 1996;56(5):409-414.
17. Ahlstrom A, Tallgren M, Peltonen S, Pettila V. Evolution and predictive power of serum cystatin C in acute renal failure. Clin Nephrol. 2004; 62(5):344-350.
18. Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995;47(1):312-318.
19. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221-226.
20. Rickli H, Benou K, Ammann P, et al. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol. 2004;61(2):98-102.
21. Jayagopal V, Keevil BG, Atkin SL, Jennings PE, Kilpatrick ES. Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. Clin Chem. 2003;49(4):680-681.
22. Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 2003;63(5): 1944-1947.
23. Risch L, Herklotz R, Blumberg A, Huber AR. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem. 2001;47(11):2055-2059.
24. Briguori C, Visconti G, Rivera N V, et al. Cystatin C and contrast-induced acute kidney injury. Circulation. 2010;121(19):2117-2122.
25. Solomon RJ, Mehran R, Natarajan MK, et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol. 2009;4(7):1162-1169.
26. Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115(3):610-621.
27. Mishra J, Ma Q, Kelly C, et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol. 2006;21(6): 856-863.
28. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography. Nephrol Dial Transplant. 2007;22(1):295-296.
29. Hirsch R, Dent C, Pfriem H, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol. 2007;22(12):2089-2095.
30. Hemdahl AL, Gabrielsen A, Zhu C, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol. 2006;26(1):136-142.
31. Ichimura T, Bonventre J V, Bailly V, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998;273(7):4135-4142.
32. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre J V. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237-244.
33. Arici M, Usalan C, Altun B, et al. Radiocontrast-induced nephrotoxicity and urinary alpha-glutathione S-transferase levels: effect of amlodipine administration. Int Urol Nephrol. 2003;35(2):255-261.
34. Beeri R, Symon Z, Brezis M, et al. Rapid DNA fragmentation from hypoxia along the thick ascending limb of rat kidneys. Kidney Int. 1995; 47(6):1806-1810.
35. Hizoh I, Haller C. Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stress. Invest Radiol. 2002;37(8): 428-434.
36. Katholi RE, Woods WT, Taylor GJ, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32(1):64-71.
37. Erley CM, Heyne N, Rossmeier S, Vogel T, Risler T, Osswald H. Adenosine and extracellular volume in radiocontrast media-induced nephropathy. Kidney Int Suppl. 1998;67:S192-S194.
38. Ya o K, Heyne N, Erley CM, Risler T, Osswald H. The selective adenosine A1 receptor antagonist KW-3902 prevents radiocontrast media-induced nephropathy in rats with chronic nitric oxide defciency. Eur J Pharmacol. 2001;414(1):99-104.
39. Liss P, Nygren A, Olsson U, Ulfendahl HR, Erikson U. Effects of contrast media and mannitol on renal medullary blood fow and red cell aggregation in the rat kidney. Kidney Int. 1996;49(5):1268-1275.
40. Liss P. Effects of contrast media on renal microcirculation and oxygen tension. An experimental study in the rat. Acta Radiol Suppl. 1997;409: 1-29.
41. Nygren A, Ulfendahl HR. Effects of high- and low-osmolar contrast media on renal plasma fow and glomerular fltration rate in euvolaemic and dehydrated rats. A comparison between ioxithalamate, iopamidol, iohexol and ioxaglate. Acta Radiol. 1989;30(4):383-389.
42. Sendeski M, Patzak A, Persson PB. Constriction of the vasa recta, the vessels supplying the area at risk for acute kidney injury, by four different iodinated contrast media, evaluating ionic, nonionic, mono-meric and dimeric agents. Invest Radiol. 2010;45(8):453-457.
43. Liss P, Nygren A, Hansell P. Hypoperfusion in the renal outer medulla after injection of contrast media in rats. Acta Radiol. 1999;40(5): 521-527.
44. Katzberg RW, Morris TW, Burgener FA, Kamm DE, Fischer HW. 1977 Memorial Award Paper. Renal renin and hemodynamic responses to selective renal artery catheterization and angiography. Invest Radiol. 1990;25(4):453-460.
45. Seeliger E, Flemming B, Wronski T, et al. Viscosity of contrast media perturbs renal hemodynamics. J Am Soc Nephrol. 2007;18(11): 2912-2920.
46. Mockel M, Radovic M, Kuhnle Y, et al. Acute renal haemodynamic effects of radiocontrast media in patients undergoing left ventricular and coronary angiography. Nephrol Dial Transplant. 2008;23(5): 1588-1594.
47. Weisberg LS, Kurnik PB, Kurnik BR. Radiocontrast-induced neph-ropathy in humans: role of renal vasoconstriction. Kidney Int. 1992; 41(5):1408-1415.
48. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol. 1995;6(5): 1451-1458.
49. Cantley LG, Spokes K, Clark B, McMahon EG, Carter J, Epstein FH. Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int. 1993;44(6):1217-1223.
50. Clark BA, Kim D, Epstein FH. Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis. 1997;30(1):82-86.
51. Mikkonen R, Lehto T, Koistinen V, Aronen HJ, Kivisaari L, Meri S. Suppression of alternative complement pathway activity by radiographic contrast media. Scand J Immunol. 1997;45(4):371-377.
52. Modi KS, Rao VK. Atheroembolic renal disease. J Am Soc Nephrol. 2001;12(8):1781-1787.
53. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95(1): 13-19.
54. Toprak O. Risk markers for contrast-induced nephropathy. Am J Med Sci. 2007;334(4):283-290.
55. Toprak O, Cirit M, Yesil M, et al. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant. 2007;22(3): 819-826.
56. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393-1399.
57. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44(9):1780-1785.
58. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002;90(10):1068-1073.
59. Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int. 2005;67(2):706-713.
60. Hill JA, Winniford M, Cohen MB, et al. Multicenter trial of ionic versus nonionic contrast media for cardiac angiography. The Iohexol Cooperative Study. Am J Cardiol. 1993;72(11):770-775.
61. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insuffciency. J Am Coll Cardiol. 2000;36(5):1542-1548.
62. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA. 1996;275(19):1489-1494.
63. Gruberg L, Mehran R, Dangas G, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv. 2001;52(4):409-416.
64. Hall KA, Wong RW, Hunter GC, et al. Contrast-induced nephrotoxicity: the effects of vasodilator therapy. J Surg Res. 1992;53(4): 317-320.
65. Uddin MA, Rabbani MA, Jafary FH, Bhatti MA, Islam M. Contrast nephropathy in high-risk patients undergoing coronary angiography and intervention. J Coll Physicians Surg Pak. 2005;15(12):791-794.
66. Guitterez N V, Diaz A, Timmis GC, et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol. 2002;15(5):349-354.
67. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast-associated renal dysfunction: incidence and risk factors. AJR Am J Roentgenol. 1991;157(1):49-58.
68. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol. 2004;94(3):300-305.
69. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med. 1990;89(5):615-620.
70. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362(9384):598-603.
71. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989;86(6 Pt 1):649-652.
72. Albert SG, Shapiro MJ, Brown W W, et al. Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance. Invest Radiol. 1994;29(6):618-623.
73. Rosovsky MA, Rusinek H, Berenstein A, Basak S, Setton A, Nelson PK. High-dose administration of nonionic contrast media: a retrospective review. Radiolog y. 1996;200(1):119-122.
74. Kahn JK, Rutherford BD, McConahay DR, et al. High-dose contrast agent administration during complex coronary angioplasty. Am Heart J. 1990;120(3):533-536.
75. Sherwin PF, Cambron R, Johnson JA, Pierro JA. Contrast dose- to-creatinine clearance ratio as a potential indicator of risk for radiocontrast-induced nephropathy: correlation of D/CrCL with area under the contrast concentration-time curve using iodixanol. Invest Radiol. 2005;40(9):598-603.
76. Laskey WK, Jenkins C, Selzer F, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50(7):584-590.
77. Nozue T, Michishita I, Iwaki T, Mizuguchi I, Miura M. Contrast medium volume to estimated glomerular fltration rate ratio as a predictor of contrast-induced nephropathy developing after elective percutaneous coronary intervention. J Cardiol. 2009;54(2):214-220.
78. Nyman U, Bjork J, Aspelin P, Marenzi G. Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention. Acta Radiol. 2008;49(6):658-667.
79. Marenzi G, Assanelli E, Campodonico J, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med. 2009;150(3): 170-177.
80. Taliercio C P, Vlietstra RE, Ilstrup DM, et al. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol. 1991;17(2): 384-390.
81. Davidson C, Stacul F, McCullough PA, et al. Contrast medium use. Am J Cardiol. 2006;98(6A):42K-58K.
82. Sharma SK, Kini A. Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insuffciency: pooled analysis of the randomized trials. Catheter Cardiovasc Interv. 2005;65(3):386-393.
83. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348(6):491-499.
84. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006;48(5):924-930.
85. Laskey W, Aspelin P, Davidson C, et al. Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures. Am Heart J. 2009;158(5):822.e3-828.e3.
86. Mehran R, Nikolsky E, Kirtane AJ, et al. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study. JACC Cardiovasc Interv. 2009;2(5):415-421.
87. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51(15):1419-1428.
88. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratifcation. Am J Cardiol. 2004;93(12):1515-1519.
89. Berns AS. Nephrotoxicity of contrast media. Kidney Int. 1989;36(4): 730-740.
90. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism - a critical review. Am J Kidney Dis. 1994;24(4): 713-727.
91. Nash K, Hafeez A, Hou S. Hospital-acquired renal insuffciency. Am J Kidney Dis. 2002;39(5):930-936.
92. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331(21): 1416-1420.
93. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003;93(1):C29-C34.
94. Wróbel W, Sinkiewicz W, Gordon M, Wozniak-WiSniewska A. Oral versus intravenous hydration and renal function in diabetic patients undergoing percutaneous coronary interventions. Kardiol Pol. 2010; 8(9):1015-1020.
95. Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest. 1998;114(6):1570-1574.
96. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162(3):329-336.
97. Dussol B, Morange S, Loundoun A, Auquier P, Berland Y. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant. 2006; 21(8):2120-2126.
98. Clavijo LC, Pinto TL, Kuchulakanti PK, et al. Effect of a rapid intraarterial infusion of dextrose 5% prior to coronary angiography on frequency of contrast-induced nephropathy in high-risk patients. Am J Cardiol. 2006;97(7):981-983.
99. Krasuski RA, Beard BM, Geoghagan JD, Thompson CM, Guidera SA. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol. 2003;15(12): 699-702.
100. Bader BD, Berger ED, Heede MB, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol. 2004;62(1):1-7.
101. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31(20):2501-2555.
102. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291(19):2328-2334.
103. Briguori C, Airoldi F, D'Andrea D, et al. Renal Insuffciency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115(10): 1211-1217.
104. Ozcan EE, Guneri S, Akdeniz B, et al. Sodium bicarbonate, N- acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007;154(3): 539-544.
105. Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300(9):1038-1046.
106. From AM, Bartholmai BJ, Williams AW, Cha SS, Pflueger A, McDonald FS. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic. Clin J Am Soc Nephrol. 2008;3(1):10-18.
107. Brezis M, Rosen S. Hypoxia of the renal medulla - its implications for disease. N Engl J Med. 1995;332(10):647-655.
108. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radio-contrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol. 1999;33(2):403-411.
109. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron. 1992;62(4): 413-415.
110. Bartorelli AL, Ferrari C, Trabattoni D, et al. TCT-332: Furosemide-Induced Diuresis with Matched Hydration Compared to Standard Hydration for Prevention of Contrast-Induced Nephropathy. The MYTHOS trial. J Am Coll Cardiol. 2010;56:B77.
111. Briguori C, Visconti G, Ricciardelli B, Condorelli G; REMEDIAL II Investigators. Renal insuffciency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. EuroIntervention. 2011;6(9):1117-1122.
112. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000; 343(3):180-184.
113. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002;89(3):356-358.
114. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40(2): 298-303.
115. Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004;148(3):422-429.
116. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocar-dial Infarction N-ACC) Trial. J Am Coll Cardiol. 2010;55(20): 2201-2209.
117. ACT Trial Investigators. Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) trial: a pragmatic randomized controlled trial to evaluate the effcacy of acetylcysteine for the prevention of contrast-induced nephropathy. Trials. 2009;10:38.
118. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15(2):407-410.
119. Gare M, Haviv YS, Ben-Yehuda A, et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol. 1999;34(6):1682-1688.
120. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insuffciency. Am J Cardiol. 1999;83(2):260-263.
121. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma fow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J. 2002;143(5):894-903.
122. Stone G W, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003;290(17):2284-2291.
123. Kolonko A, Wiecek A, Kokot F. The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol. 1998;11(3):151-156.
124. Huber W, Ilgmann K, Page M, et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insuffciency: controlled, randomized, double-blinded study. Radiology. 2002; 223(3):772-779.
125. Erley CM, Duda SH, Rehfuss D, et al. Prevention of radiocontrast-media-induced nephropathy in patients with preexisting renal insuffciency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant. 1999;14(5):1146-1149.
126. Shammas NW, Kapalis MJ, Harris M, McKinney D, Coyne EP. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invasive Cardiol. 2001;13(11):738-740.
127. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant. 2004;19(11):2747-2753.
128. Bagshaw SM, Ghali WA. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med. 2005;165(10):1087-1093.
129. Neumayer HH, Gellert J, Luft FC. Calcium antagonists and renal protection. Ren Fail. 1993;15(3):353-358.
130. Neumayer HH, Junge W, Kufner A, Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant. 1989;4(12):1030-1036.
131. Carraro M, Mancini W, Artero M, et al. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Nephrol Dial Transplant. 1996;11(3):444-448.
132. Khoury Z, Schlicht JR, Como J, et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy. 1995;15(1):59-65.
133. Spangberg-Viklund B, Berglund J, Nikonoff T, Nyberg P, Skau T, Larsson R. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scand J Urol Nephrol. 1996;30(1):63-68.
134. Denton KM, Fennessy PA, Alcorn D, Anderson W P. Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli. Am J Physiol. 1992;262(3 Pt 2):F367-F372.
135. Hollenberg NK, Swartz SL, Passan DR, Williams GH. Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension. N Engl J Med. 1979;301(1):9-12.
136. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J. 1999;51(5):521-526.
137. Cirit M, Toprak O, Yesil M, et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract. 2006;104(1):c20-c27.
138. Rosenstock JL, Bruno R, Kim JK, et al. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol. 2008;40(3):749-755.
139. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 1998;31(4): 674-680.
140. Sketch MH, Whelton A, Schollmayer E, et al. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther. 2001;8(3):155-162.
141. Attallah N, Yassine L, Musial J, Ye e J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004;62(4):273-278.
142. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118(8):843-849.
143. Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insuffciency undergoing coronary angiography (PROMISS) trial - a randomized controlled study. Am Heart J. 2008;155(3):499. e1-e8.
144. Dawson P. Contrast agents in patients on dialysis. Semin Dial. 2002;15(4):232-236.
145. Vogt B, Ferrari P, Schonholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insuffciency is potentially harmful. Am J Med. 2001;111(9):692-698.
146. Lehnert T, Keller E, Gondolf K, Schaffner T, Pavenstadt H, Schollmeyer P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant. 1998;13(2):358-362.
147. Lee PT, Chou KJ, Liu C P, et al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol. 2007; 50(11):1015-1020.
148. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofltration. N Engl J Med. 2003; 349(14):1333-1340.
149. Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemo-fltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med. 2006;119(2):155-162.
150. Weisz G, Filby SJ, Cohen MG, et al. Safety and performance of targeted renal therapy: the Be-RITe! Registry. J Endovasc Ther. 2009; 16(1):1-12.